Ubs Asset Management Americas Inc Protagonist Therapeutics, Inc Transaction History
Ubs Asset Management Americas Inc
- $381 Billion
- Q3 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 368,132 shares of PTGX stock, worth $14.5 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
368,132
Previous 369,955
0.49%
Holding current value
$14.5 Million
Previous $12.8 Million
29.06%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding PTGX
# of Institutions
248Shares Held
56.7MCall Options Held
76.3KPut Options Held
114K-
Farallon Capital Management LLC San Francisco, CA5.86MShares$230 Million1.32% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$226 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.43MShares$213 Million3.89% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.22MShares$166 Million0.0% of portfolio
-
State Street Corp Boston, MA3.18MShares$125 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $1.93B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...